According to a previous study, the presence of mesenchymal–epidermal transition (MET) receptor amplification was analyzed as a second mechanism of gefitinib resistance; 20% of EGFR T790M-resistant patients among a number of lung cancer patients were observed to have increased MET receptor levels (39–41). This evidence concerns the gene EGFR and lung cancer.